TSO3 files patent applications to extend protection for faster sterilization
cycles with improved compatibility

    
    Stock symbol:TSX: TOS
    Outstanding shares: 47,863,402
    
</pre>
<p/>
<p><location>QUEBEC</location> CITY, <chron>Oct. 1</chron> /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS), an innovator in low temperature sterilization technology for medical devices in healthcare settings, through the use of ozone (a cost effective, safe and eco-friendly method) today announced that it has filed a patent application in the <location>United States</location> seeking protection in that market as well as preserving rights in many other countries of recent innovations made to its sterilization systems, which enable both significantly faster and gentler cycles.</p>
<p>This innovation will allow TSO3 to deliver sterilization cycles compatible with an increased number of simple and complex medical devices ranging from general instruments, to complex multi-channel flexible endoscopes. Cycles incorporating this technology will be added to the new STERIZONE(R) 125L Sterilizer and made available through upgrades to existing customers, once they are cleared through the appropriate regulatory authorities.</p>
<p>"The filing of this additional patent is part of our Intellectual Property strategy which brings substantial value to our Company", commented R.M. (Ric) Rumble, President and CEO of TSO3. "This is an exciting time for TSO3 as we are creating the Improved Standard in Healthcare Sterilization(TM). Increasing the speed and utility of our sterilizer means our customers will achieve improved throughput and we believe, eliminate the need for multiple low temperature sterilization technologies within Central Sterilization departments in hospitals".</p>
<p>Earlier in 2009, TSO3 outlined its plans to; increase the utility of its sterilizer though the creation of new cycles; develop relationships leading to a channel partner and increase market opportunities via expansion outside of <location>North America</location>. In line with these targets, in addition to today's announcement concerning the patent filing, TSO3 announced on <chron>September 2, 2009</chron>, that it had entered into a 90 days exclusive negotiation period with 3M, for the distribution of the STERIZONE(R) 125L Sterilizer including new cycles through 3M's Global Infection Prevention operation. "We are pleased with both our pace and progress towards stated goals", concluded <person>Mr. Rumble</person>.</p>
<p/>
<p>About TSO3</p>
<p/>
<p>TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE(R) 125L Sterilizer, is designed for sterile processing centers in the hospital environment. The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.</p>
<p>In contrast to other methods, the ozone sterilization process developed and patented by TSO3 combines attributes that answer market needs for: efficacy, costs savings, increased safety for patients and hospital staff, and a "green" environmentally safe process.</p>
<p>The TSO3 STERIZONE(R) 125L Sterilizer is cleared for commercialization by the US and Canadian regulatory agencies for sterilization of metal and heat sensitive instruments, as well as for devices with diffusion-restricted spaces, such as rigid endoscopes having a single stainless steel channel. In 2009, the Company received clearance from Health <location>Canada</location> for sterilization of additional complex medical instruments, including multi-channel flexible endoscopes.</p>
<p>For more information about TSO3, visit the Company's Web site at <a href="http://www.tso3.com">www.tso3.com</a></p>
<p/>
<p>The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.</p>
<p/>
<pre>
    
    The TSX has neither approved nor disapproved the information contained
    herein and accepts no responsibility for it.
    

For further information: Caroline Côté, Director, Corporate Communications and IR, [phone], Ext. 237, [email protected]; Source: TSO3 Inc.